SEC Comment Letter for Coherus Oncology, Inc. (CHRS) (CIK 0001512762) (CHRS) — Sep 28, 2017
Coherus Oncology, Inc. (CHRS) (CIK 0001512762)
Date: Sept. 28, 2017 · CIK: 0001512762 · Accession: 0000000000-17-034559
AI Filing Summary & Sentiment
Reasoning
Letter
September 28, 2017 Dennis Lanfear President and Chief Executive Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 Coherus BioSciences, Inc. Registration Statement on Form S-3 Filed September 22, 2017 File No. 333-220590Re: Dear Mr. Lanfear: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Benjamin Potter
Show Raw Text
September 28, 2017 Dennis Lanfear President and Chief Executive Officer Coherus BioSciences, Inc. 333 Twin Dolphin Drive, Suite 600 Redwood City, CA 94065 Coherus BioSciences, Inc. Registration Statement on Form S-3 Filed September 22, 2017 File No. 333-220590Re: Dear Mr. Lanfear: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Jeffrey Gabor at 202-551-2544 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Benjamin Potter